The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
肺动脉高压的移动健康干预 (MOVE PAH) 研究
基本信息
- 批准号:10723261
- 负责人:
- 金额:$ 76.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
ABSTRACT
Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and
impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years. This grim
fact underscores the need to develop interventions that improve HRQOL, particularly targeting mechanisms
that are non-redundant to existing PAH therapies. Increasing physical activity is highly efficacious in PAH,
resulting in six-minute walk distance (6MWD) and HRQOL improvement that often exceeds the effect of
medications. Prior activity studies required inpatient rehabilitation, which is impractical, hard to sustain, and
poorly scalable to a rare disease. Moreover, rehabilitation for PAH is not typically reimbursed by insurance in
the United States, highlighting the need for alternatives to promote physical activity. This application builds on
a recently-completed, NIH-funded pilot and feasibility trial of a mobile health (mHealth) intervention in PAH. In
the pilot, subjects wore a Fitbit device and were randomized to either usual care or a fully automated “smart
text” intervention. Text content was based on behavioral change theory and personalized to each subject.
Texts were sent to the intervention arm 3 times/day with encouraging messages based on real-time activity
data. Each subject had a personalized step count target which increased by 20% every 4 weeks. At the end of
12 weeks, the intervention arm took 1019 more steps per day than the control arm, an increase of 20% over
baseline. We now hypothesize that increasing step counts will improve HRQOL in patients with PAH. We
propose a randomized trial of smart texts versus usual care for 6 months. We will randomize 100 PAH patients
to the mHealth intervention or usual care. All enrollment, monitoring, and data collection will occur remotely at
Vanderbilt. We will enroll subjects across the United States, increasing generalizability. Our enrollment targets
are feasible because we are supported by two large, existing PAH cohorts – the NIH-funded PVDOMICS
Consortium and the Pulmonary Hypertension Association Registry. R61 Milestones (Year 1): IRB approval;
establish DSMB; create REDCap database; Data Use Agreements; programming of text intervention;
enrollment of first 10 subjects. In Aim 1 (primary endpoint), we will test the effect of a text-based mHealth
intervention on HRQOL in PAH using the PAH-specific emPHasis-10 questionnaire. In Aim 2 (secondary
endpoint), we will test the effect of an mHealth intervention on exercise capacity, measured by a highly feasible
and reproducible supervised home-based 6MWD test. In an exploratory aim, we will examine the effect of the
intervention on time to clinical worsening (composite of PAH therapy escalation, PAH hospitalization, and
death) one year after randomization. This proposal will test a novel, highly scalable, and affordable mHealth
intervention to improve clinically meaningful outcomes in patients with PAH.
抽象的
肺动脉高压(PAH)患者的生活质量降低(HRQOL)和
运动能力受损。尽管有14种批准的疗法,但大多数患者在十年内死亡。这个严峻的
事实强调了开发改善HRQOL的干预措施的需求,尤其是针对机制
对于现有的PAH疗法而言是非冗余的。体育锻炼的增加在PAH中高效,
导致步行六分钟的距离(6MWD)和HRQOL改善通常超过
药物。先前的活动研究需要住院康复,这是不切实际的,难以维持的,并且
对罕见疾病的可扩展性不佳。此外,PAH的康复通常不会由保险偿还
美国强调需要促进体育锻炼的替代方案。此应用程序建立在
最近完成的NIH资助的飞行员和移动健康(MHealth)干预PAH的可行性试验。在
飞行员,受试者戴了Fitbit设备,并随机分配给通常的护理或全自动的“智能
文本干预。文本内容基于行为改变理论,并对每个主题进行个性化。
根据实时活动,文本被发送3次,每天3次,令人鼓舞的消息
数据。每个受试者的个性化步骤计数目标每4周增加20%。在
12周,干预臂每天的步骤比控制臂多1019个,增加了20%
基线。现在,我们假设增加的步骤计数将改善PAH患者的HRQOL。我们
提议智能文本的随机试验与通常的护理6个月。我们将随机分别100名PAH患者
进行MHealth干预或通常的护理。所有注册,监控和数据收集都将在
范德比尔特。我们将在美国各地注册受试者,从而提高普遍性。我们的入学目标
之所以可行,是因为我们得到了两个大型现有的PAH队列的支持 - NIH资助的Pvdomics
财团和肺动脉高压协会注册中心。 R61里程碑(1年):IRB批准;
建立DSMB;创建REDCAP数据库;数据使用协议;文本干预的编程;
入学前10名受试者。在AIM 1(主要终点)中,我们将测试基于文本的MHealth的效果
使用PAH特异性重点10调查表对PAH中HRQOL的干预。在AIM 2(次级
终点),我们将测试MHealth干预对运动能力的影响,该锻炼能力是由高度可行的
以及可重现的基于家庭的6MWD测试。为了探索目的,我们将研究
临床担心的时间干预(PAH治疗升级,PAH住院和
随机化一年后死亡)。该建议将测试一部小说,高度扩展且负担得起的MHealth
干预措施以改善PAH患者的临床有意义的结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Evan L Brittain其他文献
Aortic insufficiency following transcatheter aortic valve replacement is underestimated by echocardiography compared with cardiac MRI
- DOI:
10.1186/1532-429x-16-s1-o101 - 发表时间:
2014-01-16 - 期刊:
- 影响因子:
- 作者:
Wissam M Abdallah;Chris A Semder;Evan L Brittain;Michael T Baker;Lisa A Mendes;Marshall H Crenshaw;Joseph L Fredi;Mark A Robbins;Sonia L Scalf;William S Bradham;Sean G Hughes;Mark A Lawson;David X Zhao - 通讯作者:
David X Zhao
Evan L Brittain的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Evan L Brittain', 18)}}的其他基金
Impact of Physical Activity, Sleep, and Genetic Background on Cardiovascular Risk in the All of Us Program
“我们所有人”计划中体力活动、睡眠和遗传背景对心血管风险的影响
- 批准号:
10795533 - 财政年份:2023
- 资助金额:
$ 76.87万 - 项目类别:
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
肺动脉高压的移动健康干预 (MOVE PAH) 研究
- 批准号:
10525960 - 财政年份:2022
- 资助金额:
$ 76.87万 - 项目类别:
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension
网络医学和系统药理学推进联合肺动脉高压的精准医学
- 批准号:
10625481 - 财政年份:2022
- 资助金额:
$ 76.87万 - 项目类别:
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension
网络医学和系统药理学推进联合肺动脉高压的精准医学
- 批准号:
10467751 - 财政年份:2022
- 资助金额:
$ 76.87万 - 项目类别:
Effect of PDE5 Inhibition on Adipose Metabolism in Humans
PDE5 抑制对人体脂肪代谢的影响
- 批准号:
10557112 - 财政年份:2021
- 资助金额:
$ 76.87万 - 项目类别:
Effect of PDE5 Inhibition on Adipose Metabolism in Humans
PDE5 抑制对人体脂肪代谢的影响
- 批准号:
10333359 - 财政年份:2021
- 资助金额:
$ 76.87万 - 项目类别:
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure
心力衰竭肺动脉高压的临床、遗传和蛋白质组学危险因素
- 批准号:
10163899 - 财政年份:2019
- 资助金额:
$ 76.87万 - 项目类别:
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure
心力衰竭肺动脉高压的临床、遗传和蛋白质组学危险因素
- 批准号:
9913572 - 财政年份:2019
- 资助金额:
$ 76.87万 - 项目类别:
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart Failure
心力衰竭肺动脉高压的临床、遗传和蛋白质组学危险因素
- 批准号:
10394320 - 财政年份:2019
- 资助金额:
$ 76.87万 - 项目类别:
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
PDE5 抑制治疗肥胖相关的心脏代谢功能障碍
- 批准号:
9113813 - 财政年份:2016
- 资助金额:
$ 76.87万 - 项目类别:
相似国自然基金
基于信息论的健康监护过程智能化方法研究
- 批准号:62306110
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
事半功倍还是适得其反?虚拟影响者健康营销的效果、机制与策略研究
- 批准号:72302249
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
大气污染物对青少年心理健康的影响机制研究
- 批准号:42377437
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于磁-热场映射参数解耦辨识的永磁体健康状态监测方法研究
- 批准号:52307048
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于数字健康技术手段的高原牧区糖尿病患者治疗管理研究
- 批准号:72364032
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
相似海外基金
Share plus: Continuous Glucose Monitoring with Data Sharing in Older Adults with T1D and Their Care Partners
分享加:患有 T1D 的老年人及其护理伙伴的持续血糖监测和数据共享
- 批准号:
10660793 - 财政年份:2023
- 资助金额:
$ 76.87万 - 项目类别:
Mindfulness and Behavior Change to Reduce Cardiovascular Disease Risk in Older People with HIV
正念和行为改变可降低老年艾滋病毒感染者的心血管疾病风险
- 批准号:
10762220 - 财政年份:2023
- 资助金额:
$ 76.87万 - 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
- 批准号:
10761602 - 财政年份:2023
- 资助金额:
$ 76.87万 - 项目类别:
Automated Assessment of Maternal Sensitivity to Infant Distress: Leveraging Wearable Sensors for Substance Use Disorder Prevention and Research
自动评估母亲对婴儿痛苦的敏感性:利用可穿戴传感器进行药物滥用障碍预防和研究
- 批准号:
10777818 - 财政年份:2023
- 资助金额:
$ 76.87万 - 项目类别: